These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20068398)

  • 1. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
    Peipp M; Dechant M; Valerius T
    MAbs; 2009; 1(6):590-9. PubMed ID: 20068398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
    Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
    J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
    Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor as a target for anti-cancer agent design.
    Cao J; Fang H; Wang B; Ma C; Xu W
    Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?
    Sabbatino F; Ferrone S
    Clin Cancer Res; 2013 Mar; 19(5):958-60. PubMed ID: 23340298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of an anti-epidermal growth factor receptor in treating cancer.
    Waksal HW
    Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies targeting the epidermal growth factor receptor.
    Bianco R; Daniele G; Ciardiello F; Tortora G
    Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB-targeted therapeutic approaches in human cancer.
    Arteaga CL
    Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the ERBB family in cancer: couples therapy.
    Tebbutt N; Pedersen MW; Johns TG
    Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.
    Dempke WCM; Heinemann V
    Eur J Cancer; 2009 May; 45(7):1117-1128. PubMed ID: 19124237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
    Sun GC; Yang X; Yu Y; Zhao DW
    Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
    Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
    Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
    Moreira J; Tobias A; O'Brien MP; Agulnik M
    Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB receptors as targets for breast cancer therapy.
    Albanell J; Baselga J
    J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):337-51. PubMed ID: 10705918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
    Markovic A; Chung CH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.